149 related articles for article (PubMed ID: 21373201)
1. Genetic variability of the mTOR pathway and prostate cancer risk in the European Prospective Investigation on Cancer (EPIC).
Campa D; Hüsing A; Stein A; Dostal L; Boeing H; Pischon T; Tjønneland A; Roswall N; Overvad K; Østergaard JN; Rodríguez L; Sala N; Sánchez MJ; Larrañaga N; Huerta JM; Barricarte A; Khaw KT; Wareham N; Travis RC; Allen NE; Lagiou P; Trichopoulou A; Trichopoulos D; Palli D; Sieri S; Tumino R; Sacerdote C; van Kranen H; Bueno-de-Mesquita HB; Hallmans G; Johansson M; Romieu I; Jenab M; Cox DG; Siddiq A; Riboli E; Canzian F; Kaaks R
PLoS One; 2011 Feb; 6(2):e16914. PubMed ID: 21373201
[TBL] [Abstract][Full Text] [Related]
2. Two novel PRKCI polymorphisms and prostate cancer risk in an Eastern Chinese Han population.
Li Q; Gu C; Zhu Y; Wang M; Yang Y; Wang J; Jin L; Zhu ML; Shi TY; He J; Ye D; Wei Q
Mol Carcinog; 2015 Aug; 54(8):632-41. PubMed ID: 24510606
[TBL] [Abstract][Full Text] [Related]
3. Association of polymorphisms in PRKCI gene and risk of prostate cancer in a sample of Iranian Population.
Hashemi M; Shahkar G; Simforoosh N; Basiri A; Ziaee SA; Narouie B; Taheri M
Cell Mol Biol (Noisy-le-grand); 2015 Oct; 61(5):16-21. PubMed ID: 26475383
[TBL] [Abstract][Full Text] [Related]
4. Genetic variability of the fatty acid synthase pathway is not associated with prostate cancer risk in the European Prospective Investigation on Cancer (EPIC).
Campa D; Hüsing A; Chang-Claude J; Dostal L; Boeing H; Kröger J; Tjønneland A; Roswall N; Overvad K; Dahm CC; Rodríguez L; Sala N; Pérez MJ; Larrañaga N; Chirlaque MD; Ardanaz E; Khaw KT; Wareham N; Allen NE; Travis RC; Trichopoulou A; Naska A; Bamia C; Palli D; Sieri S; Tumino R; Sacerdote C; van Kranen HJ; Bas Bueno-de-Mesquita H; Stattin P; Johansson M; Chajes V; Rinaldi S; Romieu I; Siddiq A; Norat T; Riboli E; Kaaks R; Canzian F
Eur J Cancer; 2011 Feb; 47(3):420-7. PubMed ID: 20965718
[TBL] [Abstract][Full Text] [Related]
5. Energy balance, polymorphisms in the mTOR pathway, and renal cell carcinoma risk.
Shu X; Lin J; Wood CG; Tannir NM; Wu X
J Natl Cancer Inst; 2013 Mar; 105(6):424-32. PubMed ID: 23378641
[TBL] [Abstract][Full Text] [Related]
6. Intratumoral Heterogeneity Determines the Expression of mTOR-pathway Proteins in Prostate Cancer.
Russo GI; Hennenlotter J; Vogel U; Kühs U; Wurm TM; Gerber V; Neumann T; Cimino S; Stenzl A; Todenhöfer T
Dis Markers; 2019; 2019():1296865. PubMed ID: 31885728
[TBL] [Abstract][Full Text] [Related]
7. Association between Prostinogen (KLK15) genetic variants and prostate cancer risk and aggressiveness in Australia and a meta-analysis of GWAS data.
Batra J; Lose F; O'Mara T; Marquart L; Stephens C; Alexander K; Srinivasan S; Eeles RA; Easton DF; Al Olama AA; Kote-Jarai Z; Guy M; Muir K; Lophatananon A; Rahman AA; Neal DE; Hamdy FC; Donovan JL; Chambers S; Gardiner RA; Aitken J; Yaxley J; Kedda MA; Clements JA; Spurdle AB
PLoS One; 2011; 6(11):e26527. PubMed ID: 22132073
[TBL] [Abstract][Full Text] [Related]
8. mTOR is a fine tuning molecule in CDK inhibitors-induced distinct cell death mechanisms via PI3K/AKT/mTOR signaling axis in prostate cancer cells.
Berrak O; Arisan ED; Obakan-Yerlikaya P; Coker-Gürkan A; Palavan-Unsal N
Apoptosis; 2016 Oct; 21(10):1158-78. PubMed ID: 27484210
[TBL] [Abstract][Full Text] [Related]
9. Characterizing associations and SNP-environment interactions for GWAS-identified prostate cancer risk markers--results from BPC3.
Lindstrom S; Schumacher F; Siddiq A; Travis RC; Campa D; Berndt SI; Diver WR; Severi G; Allen N; Andriole G; Bueno-de-Mesquita B; Chanock SJ; Crawford D; Gaziano JM; Giles GG; Giovannucci E; Guo C; Haiman CA; Hayes RB; Halkjaer J; Hunter DJ; Johansson M; Kaaks R; Kolonel LN; Navarro C; Riboli E; Sacerdote C; Stampfer M; Stram DO; Thun MJ; Trichopoulos D; Virtamo J; Weinstein SJ; Yeager M; Henderson B; Ma J; Le Marchand L; Albanes D; Kraft P
PLoS One; 2011 Feb; 6(2):e17142. PubMed ID: 21390317
[TBL] [Abstract][Full Text] [Related]
10. Energy balance, the PI3K-AKT-mTOR pathway genes, and the risk of bladder cancer.
Lin J; Wang J; Greisinger AJ; Grossman HB; Forman MR; Dinney CP; Hawk ET; Wu X
Cancer Prev Res (Phila); 2010 Apr; 3(4):505-17. PubMed ID: 20354165
[TBL] [Abstract][Full Text] [Related]
11. Prostate cancer predisposition loci and risk of metastatic disease and prostate cancer recurrence.
Ahn J; Kibel AS; Park JY; Rebbeck TR; Rennert H; Stanford JL; Ostrander EA; Chanock S; Wang MH; Mittal RD; Isaacs WB; Platz EA; Hayes RB
Clin Cancer Res; 2011 Mar; 17(5):1075-81. PubMed ID: 21343373
[TBL] [Abstract][Full Text] [Related]
12. Variation in genes coding for AMP-activated protein kinase (AMPK) and breast cancer risk in the European Prospective Investigation on Cancer (EPIC).
Campa D; Claus R; Dostal L; Stein A; Chang-Claude J; Meidtner K; Boeing H; Olsen A; Tjønneland A; Overvad K; Rodríguez L; Bonet C; Sánchez MJ; Amiano P; Huerta JM; Barricarte A; Khaw KT; Wareham N; Travis RC; Allen NE; Trichopoulou A; Bamia C; Benetou V; Palli D; Agnoli C; Panico S; Tumino R; Sacerdote C; van Kranen H; Bas Bueno-de-Mesquita H; Peeters PH; van Gils CH; Lenner P; Sund M; Lund E; Gram IT; Rinaldi S; Chajes V; Romieu I; Engel P; Boutron-Ruault MC; Clavel-Chapelon F; Siddiq A; Riboli E; Canzian F; Kaaks R
Breast Cancer Res Treat; 2011 Jun; 127(3):761-7. PubMed ID: 21116708
[TBL] [Abstract][Full Text] [Related]
13. Replication of five prostate cancer loci identified in an Asian population--results from the NCI Breast and Prostate Cancer Cohort Consortium (BPC3).
Lindström S; Schumacher FR; Campa D; Albanes D; Andriole G; Berndt SI; Bueno-de-Mesquita HB; Chanock SJ; Diver WR; Ganziano JM; Gapstur SM; Giovannucci E; Haiman CA; Henderson B; Hunter DJ; Johansson M; Kolonel LN; Le Marchand L; Ma J; Stampfer M; Stevens VL; Trichopoulos D; Virtamo J; Willett WC; Yeager M; Hsing AW; Kraft P
Cancer Epidemiol Biomarkers Prev; 2012 Jan; 21(1):212-6. PubMed ID: 22056501
[TBL] [Abstract][Full Text] [Related]
14. SREBF1 Activity Is Regulated by an AR/mTOR Nuclear Axis in Prostate Cancer.
Audet-Walsh É; Vernier M; Yee T; Laflamme C; Li S; Chen Y; Giguère V
Mol Cancer Res; 2018 Sep; 16(9):1396-1405. PubMed ID: 29784665
[TBL] [Abstract][Full Text] [Related]
15. Genetic variability in the PRKCI gene and prostate cancer risk.
Campa D; Canzian F; Kaaks R
Cell Cycle; 2012 Jan; 11(2):209. PubMed ID: 22189710
[No Abstract] [Full Text] [Related]
16. Prostatic alpha-linolenic acid (ALA) is positively associated with aggressive prostate cancer: a relationship which may depend on genetic variation in ALA metabolism.
Azrad M; Zhang K; Vollmer RT; Madden J; Polascik TJ; Snyder DC; Ruffin MT; Moul JW; Brenner D; Hardy RW; Demark-Wahnefried W
PLoS One; 2012; 7(12):e53104. PubMed ID: 23285256
[TBL] [Abstract][Full Text] [Related]
17. Polymorphisms in mitochondrial genes and prostate cancer risk.
Wang L; McDonnell SK; Hebbring SJ; Cunningham JM; St Sauver J; Cerhan JR; Isaya G; Schaid DJ; Thibodeau SN
Cancer Epidemiol Biomarkers Prev; 2008 Dec; 17(12):3558-66. PubMed ID: 19064571
[TBL] [Abstract][Full Text] [Related]
18. Genetic variability of the forkhead box O3 and prostate cancer risk in the European Prospective Investigation on Cancer.
Campa D; Hüsing A; Dostal L; Stein A; Drogan D; Boeing H; Tjønneland A; Roswall N; Østergaard JN; Overvad K; Rodríguez L; Bonet C; Sánchez MJ; Larrañaga N; Huerta JM; Ardanaz E; Khaw KT; Wareham N; Travis RC; Allen NE; Trichopoulou A; Zylis D; Karapetyan T; Palli D; Sieri S; Tumino R; Vineis P; Bueno-de-Mesquita HB; Lenner P; Johansson M; Jenab M; Cox D; Siddiq A; Kaaks R; Canzian F
Oncol Rep; 2011 Oct; 26(4):979-86. PubMed ID: 21725602
[TBL] [Abstract][Full Text] [Related]
19. Genetic variations in the PI3K-PTEN-AKT-mTOR pathway are associated with distant metastasis in nasopharyngeal carcinoma patients treated with intensity-modulated radiation therapy.
Guo Q; Lu T; Chen Y; Su Y; Zheng Y; Chen Z; Chen C; Lin S; Pan J; Yuan X
Sci Rep; 2016 Nov; 6():37576. PubMed ID: 27876891
[TBL] [Abstract][Full Text] [Related]
20. Association of mTOR Pathway Markers and Clinical Outcomes in Patients with Intermediate-/High-risk Prostate Cancer: Long-Term Analysis.
Barata PC; Magi-Galluzzi C; Gupta R; Dreicer R; Klein EA; Garcia JA
Clin Genitourin Cancer; 2019 Oct; 17(5):366-372. PubMed ID: 31262501
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
